Ashland (ASH) Expected to Announce Quarterly Earnings on Tuesday

Ashland (NYSE:ASH) will likely be posting its quarterly earnings results after the market closes on Tuesday, January 28th. Analysts expect Ashland to post earnings of $0.79 per share and revenue of $429,038.33 billion for the quarter. Ashland has set its FY 2025 guidance at EPS.Individual that wish to register for the company’s earnings conference call can do so using this link.

Ashland (NYSE:ASH) last posted its quarterly earnings data on Wednesday, November 6th. The basic materials company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.28 by ($0.02). The business had revenue of $522.00 million during the quarter, compared to analyst estimates of $524.07 million. Ashland had a net margin of 7.95% and a return on equity of 7.43%. Ashland’s revenue for the quarter was up .8% on a year-over-year basis. During the same quarter last year, the business earned $0.41 earnings per share. On average, analysts expect Ashland to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Ashland Stock Up 1.1 %

Ashland stock opened at $71.54 on Tuesday. The company has a fifty day simple moving average of $74.08 and a 200 day simple moving average of $83.14. The company has a current ratio of 2.44, a quick ratio of 1.33 and a debt-to-equity ratio of 0.47. Ashland has a 1-year low of $68.14 and a 1-year high of $102.50. The company has a market cap of $3.37 billion, a P/E ratio of 21.35, a price-to-earnings-growth ratio of 1.11 and a beta of 0.87.

Ashland Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Sunday, December 15th. Investors of record on Sunday, December 1st were given a $0.405 dividend. This represents a $1.62 dividend on an annualized basis and a dividend yield of 2.26%. The ex-dividend date of this dividend was Friday, November 29th. Ashland’s dividend payout ratio is currently 48.36%.

Insiders Place Their Bets

In related news, VP Eric N. Boni sold 451 shares of Ashland stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $78.07, for a total transaction of $35,209.57. Following the completion of the sale, the vice president now directly owns 14,182 shares of the company’s stock, valued at approximately $1,107,188.74. This trade represents a 3.08 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Robin E. Lampkin sold 868 shares of the company’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $77.90, for a total value of $67,617.20. Following the completion of the transaction, the senior vice president now directly owns 2,883 shares in the company, valued at approximately $224,585.70. This represents a 23.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.02% of the company’s stock.

Analyst Upgrades and Downgrades

ASH has been the subject of a number of analyst reports. StockNews.com downgraded Ashland from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. BMO Capital Markets boosted their target price on shares of Ashland from $83.00 to $84.00 and gave the stock a “market perform” rating in a report on Wednesday, December 11th. Finally, Wells Fargo & Company cut their price target on shares of Ashland from $95.00 to $90.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Ashland currently has an average rating of “Moderate Buy” and a consensus target price of $102.00.

Ashland Company Profile

Ashland Inc provides additives and specialty ingredients in the North and Latin America, Europe, Asia Pacific, and internationally. It operates through Life Sciences, Personal Care, Specialty Additives, and Intermediates segments. The Life Sciences segment offers pharmaceutical solutions, including controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and tablet binders; nutrition solutions, such as thickeners, stabilizers, emulsifiers, and additives; and nutraceutical solutions comprising products for weight management, joint comfort, stomach and intestinal health, sports nutrition, and general wellness, as well as custom formulation, toll processing, and particle engineering solutions.